Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome

J Pediatr. 1992 Jul;121(1):49-55. doi: 10.1016/s0022-3476(05)82540-5.


Seventy girls with Turner syndrome, verified by karyotype, were randomly assigned to observation or treatment with human growth hormone (hGH), oxandrolone, or a combination of hGH plus oxandrolone for a period of 12 to 24 months, to assess the effect of treatment on growth velocity and adult height. Subsequently, all subjects received either hGH alone or hGH plus oxandrolone. Data are presented for 62 subjects treated for a period of 3 to 6 years. When compared with the anticipated growth rate in untreated patients, the growth rate after treatment with hGH, both alone and in combination with oxandrolone, showed a sustained increase for at least 6 years. Treatment is continuing in over half of the subjects; at present, 14 (82%) of 17 girls receiving hGH alone and 41 (91%) of 45 girls receiving combination therapy exceeded their expected adult heights. Thirty girls have completed treatment; mean height for these 30 patients is 151.9 cm, compared with their mean original projected adult height of 143.8 cm. We conclude that therapy with hGH, alone and in combination with oxandrolone, can result in a sustained increase in growth rate and a significant increase in adult height for most prepubertal girls with Turner syndrome.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Age Determination by Skeleton
  • Body Height / drug effects*
  • Child
  • Child, Preschool
  • Drug Combinations
  • Female
  • Growth / drug effects
  • Growth Hormone / administration & dosage
  • Growth Hormone / therapeutic use*
  • Humans
  • Oxandrolone / administration & dosage
  • Oxandrolone / therapeutic use*
  • Prospective Studies
  • Turner Syndrome / drug therapy*


  • Drug Combinations
  • Oxandrolone
  • Growth Hormone